



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

22 June 2017
EMA/376617/2017
EMA/H/C/000758

Public statement

Optaflu

Expiry of the marketing authorisation in the European Union

The marketing authorisation for Optaflu [influenza vaccine (surface antigen, inactivated, prepared in cell cultures)] expired on 5 June 2017 following the decision of the marketing authorisation holder, Seqirus GmbH, not to apply for a renewal of the marketing authorisation.

Seqirus GmbH confirmed that it did not apply for renewal of the authorisation due to commercial reasons.

Optaflu was granted marketing authorisation in the European Union (EU) on 1 June 2007 for prophylaxis of influenza for adults. The marketing authorisation was valid for a 5-year period. It was subsequently renewed for an additional 5-year period in 2012.

The European Public Assessment Report (EPAR) for Optaflu will be updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

